Pretreatment for acute exposure to diisopropylfluorophosphate: In vivo efficacy of various acetylcholinesterase inhibitors

Journal of Applied Toxicology

Volumn 31, Issue 6, 2011, Pages 515-523

  Lorke, Dietrich E ^a,b   Hasan, Mohamed Y ^a   Nurulain, Syed M ^a   Shafiullah, Mohamed ^a   Kuča, Kamil ^c   Petroianu, Georg A ^a,b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Carbamates; Cholinesterase; Cox analysis; DFP; Fluorophosphates; Organophosphate; Oximes; Prophylaxis

Indexed keywords

7 METHOXYTACRINE; AMILORIDE; CARMUSTINE; DYFLOS; METHYLENE BLUE; METOCLOPRAMIDE; OXIME; PHYSOSTIGMINE; PYRIDOSTIGMINE; RANITIDINE; TACRINE; TIAPRIDE;

ARTICLE; BRAIN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

CARBAMATES; CHOLINESTERASE; COX ANALYSIS; DFP; FLUOROPHOSPHATES; ORGANOPHOSPHATE; OXIMES; PROPHYLAXIS;

AMILORIDE; ANIMALS; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; ISOFLUROPHATE; MALE; METHYLENE BLUE; METOCLOPRAMIDE; OXIMES; PHYSOSTIGMINE; PROPORTIONAL HAZARDS MODELS; PYRIDINIUM COMPOUNDS; PYRIDOSTIGMINE BROMIDE; RANITIDINE; RATS; TACRINE; TIAPRIDE HYDROCHLORIDE;

ANIMALIA; RATTUS;

EID: 80051986601     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1589     Document Type: Article

References (70)

1. Antonijevic B, Stojiljkovic MP. 2007. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin. Med. Res. 5(1): 71-82.
2. Bajgar J. 2004. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem. 38: 151-216.
3. Balali-Mood M, Shariat M. 1998. Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes. J. Physiol. Paris 92(5-6): 375-378.
4. Blomqvist G, Tavitian B, Pappata S, Crouzel C, Jobert A, Doignon I, Di Giamberardino L. 2001. Quantitative measurement of cerebral acetylcholinesterase using. J. Cereb. Blood Flow Metab. 21(2): 114-31.
5. Buckley NA, Eddleston M, Dawson AH. 2005. The need for translational research on antidotes for pesticide poisoning. Clin. Exp. Pharmacol. Physiol. 32(11): 999-1005.
6. Chemnitius JM, Haselmeyer KH, Gonska BD, Kreuzer H, Zech R. 1996. Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood. Pharmacol. Res. 34(1-2): 65-72.
7. Cingolani HE, Ennis IL. 2007. Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation 115(9): 1090-1100.
8. Cox DR. 1972. Regression models and life tables. J. R. Statist. Soc. 34: 189-220.
9. Diener W, Schlede E. 1999. Acute toxic class methods: alternatives to LD/LC50 tests. ALTEX 16(3): 129-134.
10. Dunn MA, Hackley BE, Sidell FR. 1997. Pretreatment for nerve agent exposure. In Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare, Sidell FR, Takafuji ET, Franz DR (eds). Washington, DC: Borden Institute, Walter Reed Army Medical Center; 181-196.
11. Eddleston M, Dawson A, Karalliedde L, Dissanayake W, Hittarage A, Azher S, Buckley NA. 2004. Early management after self-poisoning with an organophosphorus or carbamate pesticide - a treatment protocol for junior doctors. Crit. Care 8(6): R391-397.
12. Eddleston M, Buckley NA, Eyer P, Dawson AH. 2008. Management of acute organophosphorus pesticide poisoning. Lancet 371(9612): 597-607.
13. Ellman GL, Courtney KD, Andres V, Jr., Feather-Stone RM. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7: 88-95.
14. Ferreri F, Agbokou C, Gauthier S. 2006. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J. Psychiat. Neurosci 31(6): 369-376.
15. Fontaine J, Reuse J. 1980. The effects of substituted benzamides on frog rectus abdominis. Eur. J. Pharmacol. 68(1): 55-60.
16. Gales BJ, Gales MA. 2007. Pyridostigmine in the treatment of orthostatic intolerance. Ann. Pharmacother. 41(2): 314-318.
17. Galli A, Mori F. 1991. Effectiveness of 1, 2, 3, 4-tetrahydro-9-aminoacridine (THA) as a pretreatment drug for protection of mice from acute diisopropylfluorophosphate (DFP) intoxication. Arch. Toxicol. 65(4): 330-334.
18. Grant SM, Langtry HD, Brogden RN. 1989. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37(6): 801-870.
19. Gunnell D, Eddleston M, Phillips MR, Konradsen F. 2007. The global distribution of fatal pesticide self-poisoning: systematic review. BMC Pub. Health 7: 357.
20. Gupta RC. 2006. Classification and uses of organophosphates and carbamates. In Toxicology of Organophosphate and Carbamate Compounds, Gupta RC (ed). Amsterdam: Elsevier; 5-24.
21. Johnson MK, Jacobsen D, Meredith TJ, Eyer P, Heath AJ, Ligtenstein DA, Marrs TC, Szinicz L, Vale JA, Haines JA. 2000. Evaluation of antidotes for poisoning by organophosphourus pesticides. Emerg. Med. 12(1): 22-37.
22. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V. 1994. Ketamine inhibits the anticholinesterase activity of ranitidine and physostigmine. Gen. Pharmacol. 25(4): 631-634.
23. Kuca K, Cabal J, Kassa J. 2005. A comparison of the potency of newly developed oximes (K005, K027, K033, K048) and currently used oximes (pralidoxime, obidoxime, HI-6) to reactivate sarin-inhibited rat brain acetylcholinesterase by in vitro methods. J. Toxicol. Environ. Hlth A 68(8): 677-686.
24. Kunes M, Svoboda Z, Kvetina J, Herout V, Herink J, Bajgar J. 2005. Intestinal single-pass in situ perfusion technique in rat: the influence of l-carnitine on absorption of 7-methoxytacrine. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 149(2): 433-435.
25. Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P. 1993. Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res. Commun. Chem. Pathol. Pharmacol. 79(2): 185-193.
26. Lallement G, Baille V, Baubichon D, Carpentier P, Collombet JM, Filliat P, Foquin A, Four E, Masqueliez C, Testylier G etal. 2002. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 23(1): 1-5.
27. Lorke DE, Hasan MY, Nurulain SM, Sheen R, Kuca K, Petroianu GA. 2007. Entry of two new asymmetric bispyridinium oximes (K-27 and K-48) into the rat brain: comparison with obidoxime. J. Appl. Toxicol. 27(5): 482-490.
28. Lorke DE, Kalasz H, Petroianu GA, Tekes K. 2008a. Entry of oximes into the brain: a review. Curr. Med. Chem. 15(8): 743-753.
29. Lorke DE, Nurulain SM, Hasan MY, Kuca K, Musilek K, Petroianu GA. 2008b. Eight new bispyridinium oximes in comparison with the conventional oximes pralidoxime and obidoxime: in vivo efficacy to protect from diisopropylfluorophosphate toxicity. J. Appl. Toxicol. 28(7): 920-8.
30. Lorke DE, Hasan MY, Arafat K, Kuca K, Musilek K, Schmitt A, Petroianu GA. 2008c. In vitro oxime protection of human red blood cell acetylcholinesterase inhibited by diisopropyl-fluorophosphate. J. Appl. Toxicol. 28(4): 422-429.
31. McCauley LA. 2006. Organophosphates and the gulf war syndrome. In Toxicology of Organophosphate and Carbamate Compounds, Gupta RC (ed.). Amsterdam: Elsevier; 69-78.
32. Miller SA, Blick DW, Kerenyi SZ, Murphy MR. 1993. Efficacy of physostigmine as a pretreatment for organophosphate poisoning. Pharmacol. Biochem. Behav. 44(2): 343-347.
33. Nurulain SM, Lorke DE, Hasan MY, Shafiullah M, Kuca K, Musilek K, Petroianu GA. 2009. Efficacy of eight experimental bispyridinium oximes against paraoxon-induced mortality: comparison with the conventional oximes pralidoxime and obidoxime. Neurotox. Res. 16(1): 60-67.
34. Oz M, Lorke DE, Petroianu GA. 2009a. Methylene blue and Alzheimer's disease. Biochem. Pharmacol. 78(8): 927-932.
35. Oz M, Lorke DE, Hasan M, Petroianu GA. 2009b. Cellular and molecular actions of methylene blue in the nervous system. Med. Res. Rev. 16 September DOI: 10.1002/med.20177.
36. Peter C, Hongwan D, Kupfer A, Lauterburg BH. 2000. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur. J. Clin. Pharmacol. 56(3): 247-250.
37. Petroianu GA, Kalasz HJ. 2007. Comparison of the ability of oximes to reactivate human RBC cholinesterases inhibited by ethyl- and methyl-paraoxon. Curr. Org. Chem. 11: 1624-1634.
38. Petroianu G, Kuhn F, Thyes C, Ewald V, Missler A. 2003a. In vitro protection of plasma cholinesterases by metoclopramide from inhibition by paraoxon. J. Appl. Toxicol. 23(1): 75-79.
39. Petroianu G, Arafat K, Kosanovic M, Saleh A, Camasamudram V, Hasan MY. 2003b. In vitro protection of red blood cell acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox). J. Appl. Toxicol. 23(6): 447-451.
40. Petroianu GA, Hasan MY, Kosanovic M, Vijayasarathy C, Saleh AM. 2003c. Metoclopramide protection of cholinesterase from paraoxon inhibition. Vet. Hum. Toxicol. 45(5): 251-253.
41. Petroianu G, Kuhn F, Arafat K, Zuleger K, Missler A. 2004a. In vitro protection of plasma cholinesterases by metoclopramide from inhibition by mipafox. J. Appl. Toxicol. 24(2): 143-146.
42. Petroianu GA, Missler A, Zuleger K, Thyes C, Ewald V, Maleck WH. 2004b. Enzyme reactivator treatment in organophosphate exposure: clinical relevance of thiocholinesteratic activity of pralidoxime. J. Appl. Toxicol. 24(6): 429-435.
43. Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Sheen R, Saleh A, Schmitt A. 2005a. Protective drugs in acute large-dose exposure to organophosphates: a comparison of metoclopramide and tiapride with pralidoxime in rats. Anesth. Analg 100(2): 382-386.
44. Petroianu GA, Schmitt A, Arafat K, Hasan MY. 2005b. Weak inhibitors protect cholinesterases from stronger inhibitors (dichlorvos): in vitro effect of tiapride. Int. J. Toxicol. 24(2): 79-86.
45. Petroianu GA, Hasan MY, Arafat K, Nurulain SM, Schmitt A. 2005c. Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of tiapride. J. Appl. Toxicol. 25(6): 562-567.
46. Petroianu GA, Arafat K, Schmitt A, Hasan MY. 2005d. Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J. Appl. Toxicol. 25(1): 60-67.
47. Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Sha Ullah M, Naseer O. 2005e. Protective agents in acute high-dose organophosphate exposure: comparison of ranitidine with pralidoxime in rats. J. Appl. Toxicol. 25(1): 68-73.
48. Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Shafiullah M, Sheen R. 2006a. Tiapride pre-treatment in acute exposure to paraoxon: comparison of effects of administration at different points-in-time in rats. Mol. Cell Biochem. 285(1-2): 79-86.
49. Petroianu GA, Hasan MY, Nurulain SM, Shafiullah M, Sheen R, Nagelkerke N. 2006b. Ranitidine in acute high-dose organophosphate exposure in rats: effect of the time-point of administration and comparison with pyridostigmine. Basic. Clin. Pharmacol. Toxicol. 99(4): 312-316.
50. Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Sheen R, Nagelkerke N. 2007. Comparison of two pre-exposure treatment regimens in acute organophosphate (paraoxon) poisoning in rats: tiapride vs. pyridostigmine. Toxicol. Appl. Pharmacol. 219(2-3): 235-240.
51. Peuskens J, Demily C, Thibaut F. 2005. Treatment of cognitive dysfunction in schizophrenia. Clin. Ther. 27(suppl. A): S25-37.
52. Pfaffendorf M, Bruning TA, Batnik HD, van Zwieten PA. 1997. The interaction between methylene blue and the cholinergic system. Br. J. Pharmacol. 122(1): 95-98.
53. Pope CN. 2006. Central nervous system effects and neurotoxicity. In Toxicology of Organophosphate and Carbamate Compounds, Gupta RC (ed.). Amsterdam: Elsevier; 271-291.
54. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. 2008. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med. 148(5): 379-397.
55. Rathmann KL, Conner CS. 2007. Alzheimer's disease: clinical features, pathogenesis, and treatment. 1984. Ann. Pharmacother. 41(9): 1499-504.
56. Robert PH, Allain H. 2001. Clinical management of agitation in the elderly with tiapride. Eur. Psychiatr. 16(suppl. 1): 42s-47s.
57. Sanchez-Fortun S, Barahona MV. 2009. Toxicity and characterization of cholinesterase-inhibition induced by diisopropyl fluorophosphate in Artemia salina larvae. Ecotoxicol. Environ. Saf. 72(3): 775-780.
58. Somani SM, Dube SN. 1989. Physostigmine - an overview as pretreatment drug for organophosphate intoxication. Int. J. Clin. Pharmacol. Ther. Toxicol. 27(8): 367-387.
59. Sung JH, Yu KH, Park JS, Tsuruo T, Kim DD, Shim CK, Chung SJ. 2005. Saturable distribution of tacrine into the striatal extracellular fluid of the rat: evidence of involvement of multiple organic cation transporters in the transport. Drug. Metab. Dispos. 33(3): 440-448.
60. Teiwes J, Toto RD. 2007. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am. J. Hypertens. 20(1): 109-117.
61. Triggle DJ, Mitchell JM, Filler R. 1998. The pharmacology of physostigmine. CNS Drug Rev. 4: 87-136.
62. Tuovinen K, Kaliste-Korhonen E, Raushel FM, Hanninen O. 1999. Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology 134(2-3): 169-178.
63. van Kampen EJ, Zijlstra WG. 1961. Standardization of hemoglobinometry II. The hemoglobincyanide method. Clin. Chim. Acta 6: 538-544.
64. Watson A, Bakshi K, Opresko D, Young R, Hauschild V, King J. 2006. Cholinesterase inhibitors as chemical warfare agents: community preparedness guidelines. In Toxicology of Organophosphate and Carbamate Compounds, Gupta RC (ed.). Amsterdam: Elsevier; 47-68.
65. Wiener SW, Hoffman RS. 2004. Nerve agents: a comprehensive review. J. Intens. Care Med. 19(1): 22-37.
66. Worek F, Mast U, Kiderlen D, Diepold C, Eyer P. 1999. Improved determination of acetylcholinesterase activity in human whole blood. Clin. Chim. Acta 288(1-2): 73-90.
67. Worek F, Eyer P, Aurbek N, Szinicz L, Thiermann H. 2007. Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol. Appl. Pharmacol. 219(2-3): 226-234.
68. Xia DY, Wang LX, Pei SQ. 1981. The inhibition and protection of cholinesterase by physostigmine and pyridostigmine against Soman poisoning in vivo. Fundam. Appl. Toxicol. 1(2): 217-221.
69. Zemach L, Segal D, Shalitin Y. 1990. The interaction of amiloride with acetylcholinesterase and butyrylcholinesterase. FEBS Lett. 263(1): 166-168.
70. Zhao B, Moochhala SM, Tham SY. 2004. Biologically active components of Physostigma venenosum. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 812(1-2): 183-192.